ニューヨークにおけるT細胞リンパ腫の臨床試験
ニューヨーク内の拠点で、T細胞リンパ腫に関する15件の研究が参加者を募集しています。
ニューヨーク内の都市
公式研究テキスト（英語）
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- 他5件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medicine, New York
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06561048BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- Memorial Sloan Kettering Cancer Center, New York
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT04752826Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- University of Rochester, Rochester
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/14更新 · NCT06724237A Study of Ruxolitinib and Duvelisib in People With Lymphoma
- Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center, New York
- 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05010005A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
- Rochester Skin Lymphoma Medical Group. PLLC, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06854653CD4CAR for CD4+ Leukemia and Lymphoma
- Albert Einstein Health Network, New York
被験者募集中第1相
12歳以上 · 全性別 · 2026/06/24更新 · NCT03829540A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
- Memorial Sloan Kettering, New York
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/16更新 · NCT05463263A Registry for People With T-cell Lymphoma
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison
- Weill Cornell Medical Center (Data Collection Only), New York
- 他2件
被験者募集中観察研究
全年齢 · 全性別 · 2026/05/20更新 · NCT05978141Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
- Icahn School of Medicine at Mount Sinai, New York
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/14更新 · NCT05996185CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
- Columbia University Irving Medical Center, New York
被験者募集中第1相
18歳以上 · 全性別 · 2025/11/10更新 · NCT06420089Tissue Repository: CTCL Collection Protocol
- Columbia University Irving Medical Center, New York
被験者募集中観察研究健康なボランティア歓迎
18歳以上 · 全性別 · 2025/11/04更新 · NCT02840747MB-105 in Patients With CD5 Positive T-cell Lymphoma
- Memorial Sloan Kettering Cancer Center, New York
被験者募集中第2相
18歳以上 · 全性別 · 2025/10/03更新 · NCT06534060Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- Columbia University, New York
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/22更新 · NCT04234048Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
被験者募集中第1相
1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。